Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • ErbB Receptors
  • Esophageal Neoplasms
  • Quinazolines

abstract

  • Gefitinib has a modest activity in second-line treatment of advanced esophageal cancer. However, the patient outcome was significantly better in female patients and in patients demonstrating high EGFR expression or SCC histology. The selection of esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR expression in their tumors or SCC histology should be considered.

publication date

  • April 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.03.4900

PubMed ID

  • 16575012

Additional Document Info

start page

  • 1612

end page

  • 9

volume

  • 24

number

  • 10